JPS59500618A - スピロ―フルオロフルオレン化合物、その製造法およびアルド―スレダクターゼ活性を阻害する組成物 - Google Patents
スピロ―フルオロフルオレン化合物、その製造法およびアルド―スレダクターゼ活性を阻害する組成物Info
- Publication number
- JPS59500618A JPS59500618A JP58501791A JP50179183A JPS59500618A JP S59500618 A JPS59500618 A JP S59500618A JP 58501791 A JP58501791 A JP 58501791A JP 50179183 A JP50179183 A JP 50179183A JP S59500618 A JPS59500618 A JP S59500618A
- Authority
- JP
- Japan
- Prior art keywords
- dione
- spiro
- fluorene
- formula
- imidazolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 47
- 150000001875 compounds Chemical class 0.000 title claims description 45
- 238000000034 method Methods 0.000 title claims description 32
- 230000000694 effects Effects 0.000 title claims description 25
- 108010053754 Aldehyde reductase Proteins 0.000 title claims description 11
- 102000016912 Aldehyde Reductase Human genes 0.000 title claims 2
- 239000000047 product Substances 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 22
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000003003 spiro group Chemical group 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- -1 methylthio, methylsulfinyl Chemical group 0.000 claims description 7
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000011541 reaction mixture Substances 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 5
- 239000001099 ammonium carbonate Substances 0.000 claims description 5
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 5
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 5
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 3
- 239000003048 aphrodisiac agent Substances 0.000 claims description 2
- 230000002509 aphrodisiac effect Effects 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 239000007795 chemical reaction product Substances 0.000 claims 2
- SQWNQOFLYDNCRP-UHFFFAOYSA-N spiro[fluorene-9,4'-imidazolidine] Chemical compound N1CNC2(C3=CC=CC=C3C=3C=CC=CC23)C1 SQWNQOFLYDNCRP-UHFFFAOYSA-N 0.000 claims 2
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 241000700159 Rattus Species 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 210000000695 crystalline len Anatomy 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 229930182830 galactose Natural products 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 208000002177 Cataract Diseases 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 150000002576 ketones Chemical class 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000000354 decomposition reaction Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 210000003934 vacuole Anatomy 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- QAHZIGHCEBUNGT-QMGFNSACSA-N (5r,6s,7s,8r,9r)-6,7,8-trihydroxy-9-(hydroxymethyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)C[C@]11C(=O)NC(=O)N1 QAHZIGHCEBUNGT-QMGFNSACSA-N 0.000 description 9
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 229940091173 hydantoin Drugs 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 229920005862 polyol Polymers 0.000 description 9
- 150000003077 polyols Chemical class 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000000600 sorbitol Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000003610 charcoal Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 241000533950 Leucojum Species 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000003288 aldose reductase inhibitor Substances 0.000 description 5
- 239000004020 conductor Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 150000003949 imides Chemical class 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 5
- 210000003497 sciatic nerve Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010007759 Cataract nuclear Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- 230000002060 circadian Effects 0.000 description 4
- 239000012954 diazonium Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000004570 mortar (masonry) Substances 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 208000029552 nuclear cataract Diseases 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- IAGDDPYFLFGQCX-UHFFFAOYSA-N 1-fluoro-9h-fluorene Chemical compound C12=CC=CC=C2CC2=C1C=CC=C2F IAGDDPYFLFGQCX-UHFFFAOYSA-N 0.000 description 3
- BNDBYDSPAZGULI-UHFFFAOYSA-N 2,7-difluoro-9h-fluorene Chemical compound FC1=CC=C2C3=CC=C(F)C=C3CC2=C1 BNDBYDSPAZGULI-UHFFFAOYSA-N 0.000 description 3
- SAKIZQTUUCRVJG-UHFFFAOYSA-N 2-fluoro-9h-fluorene Chemical compound C1=CC=C2C3=CC=C(F)C=C3CC2=C1 SAKIZQTUUCRVJG-UHFFFAOYSA-N 0.000 description 3
- SXHKHHXFAQRZOI-UHFFFAOYSA-N 2-fluorofluoren-1-one Chemical compound C1=CC=C2C3=CC=C(F)C(=O)C3=CC2=C1 SXHKHHXFAQRZOI-UHFFFAOYSA-N 0.000 description 3
- YNERKKMOKXACJW-UHFFFAOYSA-N 4-fluoro-9h-fluorene Chemical compound C1C2=CC=CC=C2C2=C1C=CC=C2F YNERKKMOKXACJW-UHFFFAOYSA-N 0.000 description 3
- CFRFHWQYWJMEJN-UHFFFAOYSA-N 9h-fluoren-2-amine Chemical compound C1=CC=C2C3=CC=C(N)C=C3CC2=C1 CFRFHWQYWJMEJN-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 206010007749 Cataract diabetic Diseases 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 208000027472 Galactosemias Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 241001474791 Proboscis Species 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 3
- 150000001323 aldoses Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000007025 diabetic cataract Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007830 nerve conduction Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NFMJLOPNVZKQHV-UHFFFAOYSA-N 1,2-difluoro-9h-fluorene Chemical compound C1=CC=C2CC3=C(F)C(F)=CC=C3C2=C1 NFMJLOPNVZKQHV-UHFFFAOYSA-N 0.000 description 2
- RILZRCJGXSFXNE-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]ethanol Chemical compound OCCC1=CC=C(OC(F)(F)F)C=C1 RILZRCJGXSFXNE-UHFFFAOYSA-N 0.000 description 2
- UUPNFNCKGJOLQE-UHFFFAOYSA-N 2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)imidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C(O)=O)C=C1 UUPNFNCKGJOLQE-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229940123934 Reductase inhibitor Drugs 0.000 description 2
- 238000006350 Schiemann fluorination reaction Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 125000000468 ketone group Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000004894 snout Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 2
- 229910001948 sodium oxide Inorganic materials 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- POMQQLMTQXTWLP-UHFFFAOYSA-N 1-methylfluoren-9-one Chemical compound C12=CC=CC=C2C(=O)C2=C1C=CC=C2C POMQQLMTQXTWLP-UHFFFAOYSA-N 0.000 description 1
- LJRFPYMJMQVHQU-UHFFFAOYSA-N 1-oxofluorene-2-carboxylic acid Chemical compound C1=CC=C2C3=CC=C(C(=O)O)C(=O)C3=CC2=C1 LJRFPYMJMQVHQU-UHFFFAOYSA-N 0.000 description 1
- GJTUKNIJISSSJE-UHFFFAOYSA-N 2,6-difluoro-9h-fluorene Chemical compound C1=C(F)C=C2C3=CC=C(F)C=C3CC2=C1 GJTUKNIJISSSJE-UHFFFAOYSA-N 0.000 description 1
- FXSCJZNMWILAJO-UHFFFAOYSA-N 2-bromo-9h-fluorene Chemical compound C1=CC=C2C3=CC=C(Br)C=C3CC2=C1 FXSCJZNMWILAJO-UHFFFAOYSA-N 0.000 description 1
- QFUPJXCUNNWZJQ-UHFFFAOYSA-N 2-bromofluoren-1-one Chemical compound C1=CC=C2C3=CC=C(Br)C(=O)C3=CC2=C1 QFUPJXCUNNWZJQ-UHFFFAOYSA-N 0.000 description 1
- QZFKVHGJAADBBM-UHFFFAOYSA-N 2-fluoro-7-methylsulfanylfluoren-1-one Chemical compound C1=C(F)C(=O)C2=CC3=CC(SC)=CC=C3C2=C1 QZFKVHGJAADBBM-UHFFFAOYSA-N 0.000 description 1
- VNYQUOAQPXGXQO-UHFFFAOYSA-N 2-iodo-9h-fluorene Chemical compound C1=CC=C2C3=CC=C(I)C=C3CC2=C1 VNYQUOAQPXGXQO-UHFFFAOYSA-N 0.000 description 1
- TYVNHAAUBQKLJG-UHFFFAOYSA-N 2-methylsulfanylfluoren-1-one Chemical compound C1=CC=C2C3=CC=C(SC)C(=O)C3=CC2=C1 TYVNHAAUBQKLJG-UHFFFAOYSA-N 0.000 description 1
- DUVNITXOTVXMCA-UHFFFAOYSA-N 3-chlorofluoren-1-one Chemical compound C1=CC=C2C3=CC(Cl)=CC(=O)C3=CC2=C1 DUVNITXOTVXMCA-UHFFFAOYSA-N 0.000 description 1
- BMWUNXCSAAMGOB-UHFFFAOYSA-N 3-fluoro-9h-fluorene Chemical compound C1=CC=C2C3=CC(F)=CC=C3CC2=C1 BMWUNXCSAAMGOB-UHFFFAOYSA-N 0.000 description 1
- LKWFSJAUQTYFSI-UHFFFAOYSA-N 3-fluorofluoren-1-one Chemical compound C1=CC=C2C3=CC(F)=CC(=O)C3=CC2=C1 LKWFSJAUQTYFSI-UHFFFAOYSA-N 0.000 description 1
- FFWCEONGEXZNFU-UHFFFAOYSA-N 4-aminofluoren-9-one Chemical compound O=C1C2=CC=CC=C2C2=C1C=CC=C2N FFWCEONGEXZNFU-UHFFFAOYSA-N 0.000 description 1
- SNJODBNAXNOOHI-UHFFFAOYSA-N 5-fluoro-2-nitro-9h-fluorene Chemical compound C1=CC(F)=C2C3=CC=C([N+](=O)[O-])C=C3CC2=C1 SNJODBNAXNOOHI-UHFFFAOYSA-N 0.000 description 1
- CNLYNYISINEZER-UHFFFAOYSA-N 6-fluoro-2-nitro-9h-fluorene Chemical compound C1=C(F)C=C2C3=CC=C([N+](=O)[O-])C=C3CC2=C1 CNLYNYISINEZER-UHFFFAOYSA-N 0.000 description 1
- IVTOGTCHWXYMEG-UHFFFAOYSA-N 8-fluoro-9h-fluoren-2-amine Chemical compound C1=CC=C(F)C2=C1C1=CC=C(N)C=C1C2 IVTOGTCHWXYMEG-UHFFFAOYSA-N 0.000 description 1
- CYSPWCARDHRYJX-UHFFFAOYSA-N 9h-fluoren-1-amine Chemical compound C12=CC=CC=C2CC2=C1C=CC=C2N CYSPWCARDHRYJX-UHFFFAOYSA-N 0.000 description 1
- FNGCZPANGGUOPU-UHFFFAOYSA-N 9h-fluoren-3-amine Chemical compound C1=CC=C2C3=CC(N)=CC=C3CC2=C1 FNGCZPANGGUOPU-UHFFFAOYSA-N 0.000 description 1
- NNHRVRJFHLVIIV-UHFFFAOYSA-N 9h-fluoren-4-amine Chemical compound C1C2=CC=CC=C2C2=C1C=CC=C2N NNHRVRJFHLVIIV-UHFFFAOYSA-N 0.000 description 1
- NVFINOHFZXRPAD-UHFFFAOYSA-N 9h-fluorene-1,2-diamine Chemical compound C1=CC=C2CC3=C(N)C(N)=CC=C3C2=C1 NVFINOHFZXRPAD-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000465527 Ammianus toi Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 101100313164 Caenorhabditis elegans sea-1 gene Proteins 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 241000551547 Dione <red algae> Species 0.000 description 1
- 241001061111 Diretmoides veriginae Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- FBTTXSPJONOPQE-UHFFFAOYSA-N FC=1C=CC(C2=CC3=CC=CC=C3C=12)=O Chemical compound FC=1C=CC(C2=CC3=CC=CC=C3C=12)=O FBTTXSPJONOPQE-UHFFFAOYSA-N 0.000 description 1
- 229920006385 Geon Polymers 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical group CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241000796522 Olene Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 101100015376 Rattus norvegicus Gnaz gene Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 235000003976 Ruta Nutrition 0.000 description 1
- 240000005746 Ruta graveolens Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 101150107869 Sarg gene Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000384512 Trachichthyidae Species 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical group C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical class C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- OKVJWADVFPXWQD-UHFFFAOYSA-N difluoroborinic acid Chemical class OB(F)F OKVJWADVFPXWQD-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- YLQWCDOCJODRMT-UHFFFAOYSA-N fluoren-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C2=C1 YLQWCDOCJODRMT-UHFFFAOYSA-N 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 229940087766 mydriacyl Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005806 ruta Nutrition 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- SCDXMQOKVWBFBD-UHFFFAOYSA-N spiro[fluorene-9,5'-imidazolidine]-2',4'-dione Chemical compound N1C(=O)NC(=O)C21C1=CC=CC=C1C1=CC=CC=C12 SCDXMQOKVWBFBD-UHFFFAOYSA-N 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US368632 | 1982-04-15 | ||
| US368630 | 1982-04-15 | ||
| US368631 | 1982-04-15 | ||
| PCT/US1983/000546 WO1983003543A1 (en) | 1982-04-15 | 1983-04-11 | Method of inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluorofluoren and spiro-difluorofluoren compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59500618A true JPS59500618A (ja) | 1984-04-12 |
| JPH0455190B2 JPH0455190B2 (enExample) | 1992-09-02 |
Family
ID=22175008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58501791A Granted JPS59500618A (ja) | 1982-04-15 | 1983-04-11 | スピロ―フルオロフルオレン化合物、その製造法およびアルド―スレダクターゼ活性を阻害する組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59500618A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113651757A (zh) * | 2021-09-16 | 2021-11-16 | 河北工业大学 | 一种含螺[芴-杂环]结构的空穴传输材料及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4181728A (en) * | 1978-11-16 | 1980-01-01 | Pfizer Inc. | Spiro-polycyclicimidazolidinedione derivatives |
-
1983
- 1983-04-11 JP JP58501791A patent/JPS59500618A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4181728A (en) * | 1978-11-16 | 1980-01-01 | Pfizer Inc. | Spiro-polycyclicimidazolidinedione derivatives |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113651757A (zh) * | 2021-09-16 | 2021-11-16 | 河北工业大学 | 一种含螺[芴-杂环]结构的空穴传输材料及其制备方法和应用 |
| CN113651757B (zh) * | 2021-09-16 | 2023-09-08 | 河北工业大学 | 一种含螺[芴-杂环]结构的空穴传输材料及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0455190B2 (enExample) | 1992-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4436745A (en) | Method of inhibiting aldose reductase activity | |
| US4127665A (en) | Thienohydantoin derivatives | |
| EP0763534B1 (de) | Arylalkyl-diazinone als Phosphodiesterase IV-Hemmer | |
| US4438272A (en) | Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones | |
| JPS6035350B2 (ja) | 右旋性スピローヒダントイン | |
| EP2518067B1 (fr) | Dérives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide et leurs applications en thérapeutique comme antagonistes de p2y12. | |
| EP1198453A2 (de) | N-(indolcarbonyl-)piperazinderivate als 5-ht2a-rezeptor liganden | |
| DE3128606A1 (de) | Hydantoinderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten | |
| EP0863898A1 (de) | Endothelin-rezeptor-antagonisten | |
| US4147780A (en) | α-Amino-phosphonous acids for inhibiting bacteria and yeast | |
| JPS607997B2 (ja) | ヒダントイン誘導体治療剤 | |
| EP0017379A1 (en) | Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives, pharmaceutical compositions thereof and process for their preparation | |
| DE1927393A1 (de) | Verfahren zur Herstellung von neuen heterocyclischen Carbonsaeuren | |
| LU81890A1 (fr) | Nouvelles spiro-polycyclo-imidazolidinediones et compostion pharmaceutique les contenant | |
| DE69723463T2 (de) | Cyclische organoselenderivate, ihre herstellung und verwendung | |
| JPS6089469A (ja) | アルド−スリダクテ−ス抑制剤としてのスピロ三環式芳香族スクシンイミド誘導体及びこれを用いた治療方法並びに薬剤組成物 | |
| IE48585B1 (en) | Spiro-furanohydantoin derivatives,process for their preparation and pharmaceutical compositions containing them | |
| JPH04247082A (ja) | 新スピロ〔４．５〕デカン化合物および医薬品組成物 | |
| JPS59500618A (ja) | スピロ―フルオロフルオレン化合物、その製造法およびアルド―スレダクターゼ活性を阻害する組成物 | |
| EP0277611A2 (de) | Alkylsubstituierte N-Benzopyranyllactame, Verfahren zu ihrer Herstellung, ihre Verwendung sowie pharmazeutische Präparate auf Basis dieser Verbindungen | |
| WO1997043284A1 (de) | Neue thiazolidindione, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| KR900003392B1 (ko) | 스피로-(모노 및 디)-플루오로플루오렌 화합물 및 그의 제조방법 | |
| US4831032A (en) | Cardiotonic benzimidazoles | |
| US4540700A (en) | Treatment of diabetic complications with certain spiro-imidazolidine-diones | |
| EP0288898B1 (de) | Substituierte Chinoxalyl-imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel sowie pharmazeutische Präparate |